Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply

Documenti analoghi

• Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme
  di: James Lok
  Pubblicazione: (2024)
• Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
  di: Terry Cheuk‐Fung Yip, et al.
  Pubblicazione: (2025)
• Editorial: HBV Integration—A Possible Key Driver on the Course of Patients With Chronic HBV Infection Under Viral Suppression. Authors' Reply
  di: Qin Ning, et al.
  Pubblicazione: (2025)
• Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC
  di: Naohiro Yasuura, et al.
  Pubblicazione: (2024)
• Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
  di: Jiong Yu, et al.
  Pubblicazione: (2024)